Matt Tector, PhD is the chief scientific officer of Makana Therapeutics, a company focused on the development and implementation of xenotransplantation as a viable clinical option for patients suffering from kidney failure. In pursuit of this goal, Dr. Tector has been part of a multifaceted team studying the compatibility of genetically engineered pig tissues with human beings for over a decade. He received his PhD from the University of Pittsburgh, studying the cell and molecular biology of molecules that are key to immunity organ transplantation. He received postdoctoral training at the Memorial Sloan-Kettering and Cancer Center and Max-Planck Institutes.